MiMedx Group (MDXG) Financials

$6.77 +0.14 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$6.77 0.00 (0.00%)

As of 04:20 PM Eastern

Annual Income Statements for MiMedx Group

This table shows MiMedx Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	42	58	-30	-29	-83	-26	-30	65	0.39	29	6.22
Consolidated Net Income / (Loss)	42	58	-30	-10	-49	-26	-30	65	0.39	29	6.22
Net Income / (Loss) Continuing Operations	42	67	-20	-12	-49	-26	-30	65	0.39	29	6.22
Total Pre-Tax Income	57	31	-20	-12	-62	-26	-3.40	45	0.55	24	7.05
Total Operating Income	59	37	-15	-7.05	-45	-21	-3.92	46	0.88	24	7.10
Total Gross Profit	289	267	220	202	209	256	323	286	191	167	106
Total Revenue	349	321	268	242	248	299	359	321	222	187	118
Operating Revenue	349	321	268	242	248	299	359	321	222	187	118
Total Cost of Revenue	60	55	48	40	39	43	36	35	31	20	13
Operating Cost of Revenue	60	55	48	40	39	43	36	35	31	20	13
Total Operating Expenses	230	230	234	209	254	277	327	240	190	143	98
Selling, General & Admin Expense	225	211	209	195	181	198	259	220	173	133	90
Research & Development Expense	12	13	13	9.93	12	11	16	18	14	8.41	7.05
Amortization Expense	0.77	0.76	0.70	0.82	1.07	1.04	1.03	1.68	2.14	0.93	0.93
Other Operating Expenses / (Income)	-8.70	5.18	12	3.79	59	67	51	0.00	0.00	-	-
Impairment Charge	0.45	0.00	0.00	0.05	1.03	0.45	0.00	0.00	-	-	-
Total Other Income / (Expense), net	-1.57	-6.48	-5.02	-5.00	-16	-4.43	0.53	-1.14	-0.34	-0.09	-0.05
Interest & Investment Income	-1.01	-6.46	-5.02	-	-	-	-	-	-	-	-
Other Income / (Expense), net	-0.57	-0.03	-0.00	-0.02	-0.00	0.28	0.00	-1.05	-0.34	-	-
Income Tax Expense	15	-37	0.21	0.25	-12	-0.01	27	-20	0.16	-5.17	0.83
Net Income / (Loss) Discontinued Operations	0.42	-9.21	-10	2.02	-	-	-	-	-	-	-
Basic Earnings per Share	$0.29	$0.40	($0.33)	($0.15)	($0.77)	($0.24)	($0.28)	$0.61	$0.00	$0.28	$0.06
Weighted Average Basic Shares Outstanding	146.98M	116.50M	112.91M	110.35M	108.26M	106.95M	105.60M	106.12M	105.93M	105.93M	105.79M
Diluted Earnings per Share	$0.28	$0.37	($0.33)	($0.15)	($0.77)	($0.24)	($0.28)	$0.56	$0.00	$0.26	$0.05
Weighted Average Diluted Shares Outstanding	149.05M	145.96M	112.91M	110.35M	108.26M	106.95M	105.60M	116.11M	112.65M	113.63M	113.30M
Weighted Average Basic & Diluted Shares Outstanding	147.37M	146.96M	114.08M	112.36M	111.26M	106.60M	107.10M	106.10M	108.84M	107.81M	103.70M

This table shows MiMedx Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	7.02	-9.50	16	18	18	43	16	8.72	-8.61	2.80	-8.43
Consolidated Net Income / (Loss)	7.02	7.44	8.10	18	9.26	53	8.53	1.20	-4.98	-0.41	-8.43
Net Income / (Loss) Continuing Operations	7.02	7.44	7.88	18	9.06	51	8.84	9.25	-1.94	9.83	-8.43
Total Pre-Tax Income	8.61	11	11	23	11	14	9.43	9.18	-1.89	9.86	-8.37
Total Operating Income	8.25	11	11	23	13	15	11	11	-0.34	11	-7.10
Total Gross Profit	72	76	69	72	72	73	67	68	59	60	56
Total Revenue	88	93	84	87	85	87	82	81	72	74	68
Operating Revenue	88	93	84	87	85	87	82	81	72	74	68
Total Cost of Revenue	17	17	15	15	13	14	15	14	12	14	12
Operating Cost of Revenue	17	17	15	15	13	14	15	14	12	14	12
Total Operating Expenses	63	65	58	49	59	57	56	57	60	49	63
Selling, General & Admin Expense	60	61	54	55	55	54	53	52	52	50	53
Research & Development Expense	3.33	3.57	2.92	3.01	2.84	2.43	3.08	3.67	3.48	-4.73	5.95
Amortization Expense	0.10	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.18	0.18
Other Operating Expenses / (Income)	0.00	0.04	0.65	-9.70	0.31	0.52	-0.04	1.02	3.67	3.41	3.00
Impairment Charge	0.00	0.09	0.30	0.00	0.05	-	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	0.36	0.20	0.26	-0.23	-1.79	-1.58	-1.69	-1.66	-1.55	-1.45	-1.27
Interest & Investment Income	0.51	-	0.28	0.00	-	-	-1.68	-1.63	-	-	-
Other Income / (Expense), net	-0.15	-0.21	-0.02	-0.24	-0.10	0.02	-0.01	-0.03	0.00	-0.00	0.00
Income Tax Expense	1.59	3.81	3.54	5.60	2.35	-37	0.59	-0.07	0.05	0.03	0.05
Net Income / (Loss) Discontinued Operations	0.00	-	0.22	0.00	0.20	2.19	-0.31	-8.05	-3.04	-	-
Basic Earnings per Share	$0.05	$0.06	$0.05	$0.12	$0.06	$0.40	$0.06	$0.00	($0.06)	($0.02)	($0.09)
Weighted Average Basic Shares Outstanding	147.27M	146.98M	146.96M	147.33M	146.40M	116.50M	116.30M	115.87M	114.40M	112.91M	113.45M
Diluted Earnings per Share	$0.05	$0.05	$0.05	$0.12	$0.06	$0.36	$0.06	$0.01	($0.06)	($0.02)	($0.09)
Weighted Average Diluted Shares Outstanding	149.68M	149.05M	148.37M	148.90M	150.03M	145.96M	149.77M	146.86M	114.40M	112.91M	113.45M
Weighted Average Basic & Diluted Shares Outstanding	147.70M	147.37M	146.95M	146.81M	147.60M	146.96M	116.38M	116.11M	115.60M	114.08M	113.67M

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	22	16	-21	-8.73	27	24	18	-2.85	4.02	-18	2.50
Net Cash From Operating Activities	66	27	-18	-1.98	-30	-39	36	63	24	19	17
Net Cash From Continuing Operating Activities	67	35	-7.97	-9.87	-30	-39	36	63	24	19	17
Net Income / (Loss) Continuing Operations	42	67	-20	-12	-49	-26	-30	65	0.39	29	6.22
Depreciation Expense	2.28	2.67	3.35	4.36	5.78	6.55	5.88	4.09	3.33	1.80	1.20
Amortization Expense	3.76	0.76	0.70	1.88	3.35	2.47	0.98	1.84	2.29	0.98	0.93
Non-Cash Adjustments To Reconcile Net Income	11	20	15	16	26	-2.80	15	23	19	17	11
Changes in Operating Assets and Liabilities, net	8.15	-56	-7.47	-19	-16	-20	44	-31	-1.38	-30	-3.00
Net Cash From Discontinued Operating Activities	-0.93	-8.16	-9.92	7.89	-	-	-	-	-	-	-
Net Cash From Investing Activities	-9.58	-2.16	-2.66	-3.40	-4.56	0.50	-9.22	-5.40	-12	-0.68	-12
Net Cash From Continuing Investing Activities	-9.58	-2.16	-2.66	-3.40	-4.56	0.50	-9.22	-5.40	-12	-0.68	-12
Purchase of Property, Plant & Equipment	-1.68	-1.99	-1.51	-3.22	-4.23	-1.75	-9.42	-5.13	-6.21	-5.83	-2.56
Acquisitions	-7.86	0.00	0.00	0.00	-0.33	-0.47	-0.61	-	-7.63	0.00	0.00
Other Investing Activities, net	-0.04	-0.17	-1.15	-0.25	-	-	-	-0.27	-0.84	-0.85	-0.59
Net Cash From Financing Activities	-34	-8.57	-0.58	-3.35	62	63	-8.93	-60	-8.15	-36	-2.15
Net Cash From Continuing Financing Activities	-34	-8.57	-0.58	-3.35	62	63	-8.93	-60	-8.15	-36	-2.15
Repayment of Debt	-82	-0.05	-0.04	-	-89	-8.53	-0.00	-0.03	-	-0.50	0.00
Repurchase of Common Equity	0.00	-9.52	0.00	0.00	-7.47	0.00	-7.57	-68	-10	-40	-5.61
Issuance of Debt	50	0.00	0.00	-	60	73	0.00	0.00	-	-	-
Other Financing Activities, net	-2.24	1.00	-0.54	-3.35	-1.92	-1.37	-1.36	7.91	2.23	4.56	3.47

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	2.02	16	20	21	-34	0.84	13	7.43	-4.73	-7.27	0.72
Net Cash From Operating Activities	5.30	19	20	22	5.98	10	13	7.78	-4.05	-5.62	0.96
Net Cash From Continuing Operating Activities	5.30	19	20	22	6.79	9.27	13	12	0.60	4.30	0.96
Net Income / (Loss) Continuing Operations	7.02	7.44	7.88	18	9.06	51	8.84	9.25	-1.94	9.83	-8.43
Depreciation Expense	3.20	0.56	0.58	0.58	0.56	0.61	0.65	0.69	0.71	0.80	0.83
Amortization Expense	0.14	2.21	0.79	0.50	0.26	-0.18	0.56	0.07	0.31	-0.17	0.29
Non-Cash Adjustments To Reconcile Net Income	5.34	5.13	4.21	-4.87	6.46	5.41	5.14	4.93	4.20	0.81	3.14
Changes in Operating Assets and Liabilities, net	-10	3.44	6.16	8.11	-9.56	-48	-2.10	-2.97	-2.68	-6.97	5.12
Net Cash From Discontinued Operating Activities	0.00	0.00	-0.00	-0.12	-0.81	0.99	-0.31	-4.19	-4.65	-	-
Net Cash From Investing Activities	-0.41	-2.77	0.11	-0.91	-6.02	-0.48	-0.65	-0.35	-0.68	-1.71	-0.37
Net Cash From Continuing Investing Activities	-0.41	-2.77	0.11	-0.91	-6.02	-0.48	-0.65	-0.35	-0.68	-1.71	-0.37
Purchase of Property, Plant & Equipment	-0.38	5.10	-0.17	-0.47	-6.14	-0.43	-0.63	-0.30	-0.63	-0.67	-0.35
Acquisitions	0.00	-	-	-	-	-	-	-	-	-	-
Other Investing Activities, net	-0.03	-0.01	0.28	-0.43	0.12	-0.05	-0.02	-0.05	-0.04	-1.02	-0.03
Net Cash From Financing Activities	-2.88	-0.40	0.03	-0.36	-33	-8.94	0.37	0.00	-0.00	0.07	0.13
Net Cash From Continuing Financing Activities	-2.88	-0.40	0.03	-0.36	-33	-8.94	0.37	0.00	-0.00	0.07	0.13
Repayment of Debt	0.00	0.61	-0.75	-	-82	-0.05	-	-	0.00	-	-
Issuance of Debt	0.00	-	-	-	50	-	-	-	0.00	-	-
Other Financing Activities, net	-2.88	-1.01	0.78	-0.36	-1.65	0.63	0.37	0.00	-0.00	0.11	0.13

This table presents MiMedx Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	264	239	171	188	202	167	123	121	117	136	109
Total Current Assets	192	164	134	149	161	123	74	49	59	96	86
Cash & Equivalents	104	82	66	87	96	69	45	27	30	28	47
Accounts Receivable	56	54	43	40	35	32	0.00	-	-	54	27
Inventories, net	24	21	13	11	10	9.10	16	9.47	16	7.46	5.13
Prepaid Expenses	5.02	5.62	7.32	6.15	5.61	6.67	6.67	2.13	1.84	3.39	1.54
Other Current Assets	2.82	1.75	3.34	2.81	3.37	6.06	5.82	9.02	9.52	0.22	-
Plant, Property, & Equipment, net	5.94	6.97	7.86	9.17	0.00	12	17	14	14	9.48	5.45
Total Noncurrent Assets	66	68	29	30	41	32	31	58	44	30	18
Goodwill	19	19	19	20	20	20	20	20	20	4.04	4.04
Intangible Assets	12	5.26	5.85	5.38	6.00	7.78	9.61	10	23	11	11
Noncurrent Deferred & Refundable Income Taxes	28	41	0.00	-	-	-	-	26	0.00	15	0.00
Other Noncurrent Operating Assets	6.71	2.34	3.55	4.88	15	3.84	1.79	2.87	0.35	0.49	3.25
Total Liabilities & Shareholders' Equity	264	239	171	188	202	167	123	121	117	136	109
Total Liabilities	71	96	97	95	111	133	73	47	69	28	20
Total Current Liabilities	46	46	44	42	59	67	72	46	61	27	18
Short-Term Debt	2.42	1.00	-	-	-	3.75	0.00	-	-	0.00	-
Accounts Payable	7.41	9.05	8.45	7.39	8.77	8.71	15	8.45	12	6.63	3.66
Accrued Expenses	9.01	9.36	11	9.81	30	32	32	16	19	4.64	2.50
Current Employee Benefit Liabilities	24	22	21	24	18	21	23	21	13	15	12
Other Current Liabilities	3.09	2.89	1.83	1.57	1.47	1.40	1.82	0.65	1.48	0.53	0.72
Other Current Nonoperating Liabilities	0.00	1.35	1.48	-	-	-	-	-	-	-	-
Total Noncurrent Liabilities	25	50	53	53	51	65	1.64	1.65	0.88	1.15	1.53
Long-Term Debt	18	48	49	48	48	62	0.00	-	-	-	-
Other Noncurrent Operating Liabilities	7.38	2.22	4.77	4.87	3.76	3.54	1.64	1.65	0.88	1.15	1.53
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	-	0.00	0.00
Total Equity & Noncontrolling Interests	193	143	-18	0.08	-0.15	34	50	74	48	108	89
Total Preferred & Common Equity	193	143	-18	0.08	-0.15	34	50	74	48	108	89
Total Common Equity	193	143	-18	0.08	-0.15	34	50	74	48	108	89
Common Stock	284	276	174	166	159	147	165	165	162	163	163
Retained Earnings	-91	-134	-192	-162	-151	-102	-77	-47	-111	-38	-68

This table presents MiMedx Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	270	244	230	222	189	176	168	173
Total Current Assets	200	172	154	139	155	141	132	136
Cash & Equivalents	106	89	69	48	81	69	61	73
Accounts Receivable	62	54	53	57	49	49	45	41
Inventories, net	24	24	25	24	19	17	15	14
Prepaid Expenses	5.35	2.91	4.03	6.10	2.95	3.68	8.82	4.68
Other Current Assets	1.97	2.15	3.10	2.80	2.31	3.11	2.31	2.58
Plant, Property, & Equipment, net	5.77	6.45	6.82	7.34	7.09	7.26	7.56	7.91
Total Noncurrent Assets	65	65	69	75	27	28	29	29
Goodwill	19	19	19	19	19	19	20	20
Intangible Assets	11	11	12	13	5.40	5.57	5.71	4.99
Noncurrent Deferred & Refundable Income Taxes	28	31	33	39	-	-	-	-
Other Noncurrent Operating Assets	6.35	4.02	4.41	4.75	2.59	2.89	3.21	3.88
Total Liabilities & Shareholders' Equity	270	244	230	222	189	176	168	173
Total Liabilities	68	63	62	66	95	97	94	100
Total Current Liabilities	43	42	40	42	44	44	41	46
Short-Term Debt	1.13	3.86	3.20	1.00	-	-	-	-
Accounts Payable	8.87	6.92	7.60	9.70	9.17	8.15	7.82	8.82
Accrued Expenses	9.45	8.40	9.28	9.20	9.44	13	13	11
Current Employee Benefit Liabilities	19	20	18	18	23	22	18	24
Other Current Liabilities	4.44	2.59	2.07	4.07	1.85	2.06	1.79	1.96
Total Noncurrent Liabilities	25	21	22	24	52	52	53	54
Long-Term Debt	18	18	18	18	49	49	49	48
Other Noncurrent Operating Liabilities	7.49	2.92	3.88	5.28	2.61	3.25	4.03	5.49
Total Equity & Noncontrolling Interests	203	181	168	156	1.33	-13	-18	-20
Total Preferred & Common Equity	203	181	168	156	1.33	-13	-18	-20
Total Common Equity	203	181	168	156	1.33	-13	-18	-20
Common Stock	287	280	275	280	188	183	179	172
Retained Earnings	-84	-99	-107	-124	-187	-196	-197	-191

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.52%	20.03%	10.67%	-2.50%	-17.05%	-16.67%	11.82%	44.85%	18.38%	58.43%	99.77%
EBITDA Growth	58.80%	479.20%	-1,178.11%	97.70%	-205.79%	-503.57%	-94.25%	728.80%	-77.28%	194.18%	2,327.63%
EBIT Growth	57.19%	351.78%	-108.24%	84.42%	-117.47%	-432.03%	-108.69%	8,188.99%	-97.76%	243.15%	369.04%
NOPAT Growth	-47.19%	892.63%	-108.86%	84.47%	-114.55%	-439.25%	-104.14%	10,389.68%	-97.86%	371.87%	439.00%
Net Income Growth	-27.15%	292.83%	-193.60%	79.13%	-92.67%	14.67%	-146.32%	16,496.67%	-98.68%	373.41%	251.26%
EPS Growth	-24.32%	212.12%	-120.00%	80.52%	-220.83%	14.29%	-150.00%	0.00%	-100.00%	420.00%	225.00%
Operating Cash Flow Growth	147.24%	249.64%	-802.78%	93.45%	23.21%	-210.10%	-43.13%	163.91%	26.81%	11.93%	6,016.20%
Free Cash Flow Firm Growth	66.17%	302.99%	11.81%	65.41%	-6.87%	-205.69%	-33.15%	50.60%	489.52%	-699.79%	91.16%
Invested Capital Growth	-2.00%	95.85%	5.86%	23.83%	39.75%	582.94%	-90.21%	20.76%	-49.86%	106.78%	25.46%
Revenue Q/Q Growth	1.77%	4.03%	9.65%	-6.83%	-3.07%	-5.13%	1.42%	14.62%	-2.32%	7.01%	22.33%
EBITDA Q/Q Growth	-4.21%	9.55%	46.79%	95.21%	-47.84%	27.55%	-90.22%	121.16%	-72.87%	14.14%	200.17%
EBIT Q/Q Growth	-7.40%	12.77%	40.49%	71.04%	-32.87%	16.69%	-116.27%	161.96%	-96.88%	14.57%	585.33%
NOPAT Q/Q Growth	-52.39%	153.79%	40.50%	71.14%	-32.82%	16.13%	-105.58%	259.75%	-96.88%	48.30%	520.22%
Net Income Q/Q Growth	-52.05%	1,242.59%	-9.54%	64.63%	-22.66%	52.92%	-172.91%	172.53%	-98.04%	47.97%	547.30%
EPS Q/Q Growth	-52.54%	3,800.00%	-10.00%	54.55%	-14.93%	52.94%	-177.78%	180.00%	-100.00%	44.44%	400.00%
Operating Cash Flow Q/Q Growth	14.78%	145.78%	-15.43%	78.02%	29.81%	-167.09%	-35.07%	10.86%	76.61%	-17.28%	79.57%
Free Cash Flow Firm Q/Q Growth	18.85%	45.23%	37.33%	20.49%	19.18%	-42.09%	-74.84%	115.67%	193.69%	-1,115.28%	64.61%
Invested Capital Q/Q Growth	-4.51%	80.39%	17.69%	21.60%	3.08%	172.35%	0.00%	-56.28%	-66.52%	44.48%	8.80%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.78%	83.01%	81.96%	83.63%	84.16%	85.60%	89.87%	89.03%	86.05%	89.21%	89.29%
EBITDA Margin	18.44%	12.60%	-3.99%	-0.35%	-14.61%	-3.96%	0.82%	15.91%	2.78%	14.49%	7.80%
Operating Margin	16.87%	11.55%	-5.50%	-2.91%	-18.29%	-7.07%	-1.09%	14.39%	0.40%	13.01%	6.01%
EBIT Margin	16.71%	11.54%	-5.50%	-2.92%	-18.29%	-6.98%	-1.09%	14.07%	0.25%	13.01%	6.01%
Profit (Net Income) Margin	12.16%	18.11%	-11.27%	-4.25%	-19.85%	-8.55%	-8.35%	20.16%	0.18%	15.72%	5.26%
Tax Burden Percent	74.04%	190.08%	152.92%	85.32%	80.08%	99.98%	882.51%	143.56%	71.56%	121.29%	88.20%
Interest Burden Percent	98.27%	82.59%	134.05%	170.40%	135.55%	122.55%	86.57%	99.81%	100.00%	99.65%	99.32%
Effective Tax Rate	26.70%	-120.15%	0.00%	0.00%	0.00%	0.00%	0.00%	-43.56%	28.44%	-21.29%	11.80%
Return on Invested Capital (ROIC)	39.21%	97.32%	-18.68%	-10.18%	-85.56%	-83.40%	-10.80%	156.72%	1.10%	52.07%	18.84%
ROIC Less NNEP Spread (ROIC-NNEP)	40.47%	192.60%	51.47%	2.10%	-17.61%	-39.02%	64.22%	165.49%	2.28%	52.32%	18.93%
Return on Net Nonoperating Assets (RNNOA)	-13.94%	-43.70%	-17.47%	-0.99%	7.21%	22.53%	-37.77%	-50.49%	-0.60%	-22.23%	-11.20%
Return on Equity (ROE)	25.26%	53.61%	-36.15%	-11.18%	-78.34%	-60.87%	-48.57%	106.23%	0.50%	29.85%	7.64%
Cash Return on Invested Capital (CROIC)	41.23%	32.52%	-24.37%	-31.47%	-118.72%	-232.31%	153.51%	137.92%	67.52%	-17.54%	-3.74%
Operating Return on Assets (OROA)	23.18%	18.07%	-8.20%	-3.63%	-24.59%	-14.40%	-3.22%	37.88%	0.43%	19.88%	7.32%
Return on Assets (ROA)	16.87%	28.37%	-16.81%	-5.27%	-26.70%	-17.64%	-24.56%	54.27%	0.31%	24.02%	6.41%
Return on Common Equity (ROCE)	25.26%	30.78%	3.87%	0.00%	-21.33%	-60.87%	-48.57%	106.23%	0.50%	29.85%	7.64%
Return on Equity Simple (ROE_SIMPLE)	21.97%	40.80%	167.87%	0.00%	0.00%	-74.36%	-60.37%	87.71%	0.81%	27.27%	6.96%
Net Operating Profit after Tax (NOPAT)	43	82	-10	-4.94	-32	-15	-2.75	66	0.63	30	6.26
NOPAT Margin	12.37%	25.42%	-3.85%	-2.04%	-12.80%	-4.95%	-0.76%	20.66%	0.29%	15.78%	5.30%
Net Nonoperating Expense Percent (NNEP)	-1.26%	-95.28%	-70.15%	-12.29%	-67.95%	-44.38%	-75.03%	-8.76%	-1.18%	-0.25%	-0.09%
Return On Investment Capital (ROIC_SIMPLE)	20.22%	42.60%	-33.68%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	17.22%	16.99%	18.04%	16.37%	15.84%	14.40%	10.13%	10.97%	13.95%	10.79%	10.71%
SG&A Expenses to Revenue	64.52%	65.67%	77.91%	80.51%	72.92%	66.23%	71.99%	68.54%	78.22%	71.22%	76.53%
R&D to Revenue	3.54%	3.94%	4.74%	4.10%	4.72%	3.72%	4.39%	5.57%	6.47%	4.49%	5.96%
Operating Expenses to Revenue	65.91%	71.46%	87.46%	86.54%	102.44%	92.67%	90.96%	74.64%	85.65%	76.21%	83.28%
Earnings before Interest and Taxes (EBIT)	58	37	-15	-7.07	-45	-21	-3.92	45	0.55	24	7.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	64	41	-11	-0.84	-36	-12	2.94	51	6.17	27	9.23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.32	7.15	0.00	8,260.40	0.00	24.47	5.39	18.97	20.19	9.45	13.80
Price to Tangible Book Value (P/TBV)	8.72	8.65	0.00	0.00	0.00	126.66	13.33	31.98	210.66	10.96	16.56
Price to Revenue (P/Rev)	4.05	3.17	1.18	2.80	4.06	2.81	0.75	4.36	4.38	5.45	10.43
Price to Earnings (P/E)	33.33	17.53	0.00	0.00	0.00	0.00	0.00	21.63	2,487.95	34.67	198.23
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.00%	5.71%	0.00%	0.00%	0.00%	0.00%	0.00%	4.62%	0.04%	2.88%	0.50%
Enterprise Value to Invested Capital (EV/IC)	12.20	8.88	6.89	13.63	24.29	27.05	49.04	29.63	24.50	12.93	31.91
Enterprise Value to Revenue (EV/Rev)	3.81	3.07	1.46	3.02	4.24	2.80	0.62	4.27	4.24	5.28	9.99
Enterprise Value to EBITDA (EV/EBITDA)	20.66	24.38	0.00	0.00	0.00	0.00	75.70	26.86	152.45	36.46	127.99
Enterprise Value to EBIT (EV/EBIT)	22.80	26.63	0.00	0.00	0.00	0.00	0.00	30.39	1,724.73	40.61	166.29
Enterprise Value to NOPAT (EV/NOPAT)	30.81	12.09	0.00	0.00	0.00	0.00	0.00	20.69	1,485.93	33.49	188.53
Enterprise Value to Operating Cash Flow (EV/OCF)	20.08	36.89	0.00	0.00	0.00	0.00	6.22	21.81	39.41	52.61	70.27
Enterprise Value to Free Cash Flow (EV/FCFF)	29.30	36.17	0.00	0.00	0.00	0.00	5.70	23.51	24.24	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.34	0.65	0.52	0.52	1.91	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.09	0.34	0.65	0.52	0.52	1.80	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.34	-0.23	-0.34	-0.47	-0.41	-0.58	-0.59	-0.31	-0.26	-0.42	-0.59
Leverage Ratio	1.50	1.89	2.15	2.12	2.93	3.45	1.98	1.96	1.62	1.24	1.19
Compound Leverage Factor	1.47	1.56	2.88	3.61	3.98	4.23	1.71	1.95	1.62	1.24	1.18
Debt to Total Capital	9.49%	25.60%	39.48%	34.20%	34.29%	65.62%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.13%	0.52%	0.00%	0.00%	0.00%	3.75%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.36%	25.08%	39.48%	34.20%	34.29%	61.87%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	75.14%	65.74%	65.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.51%	74.40%	-14.61%	0.06%	-0.11%	34.38%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.31	1.21	-4.55	-57.57	-1.32	-5.54	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-1.31	-0.81	1.62	46.60	1.33	0.29	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.28	1.19	-4.55	-57.57	-1.32	-5.22	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.47	0.60	-4.71	-9.75	-1.50	-4.43	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-1.95	-0.40	1.68	7.89	1.51	0.23	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.41	0.59	-4.71	-9.75	-1.50	-4.18	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.21	8.02	2.30	4.90	5.51	4.73	4.16	21.07	8.98	24.13	38.29
Noncontrolling Interest Sharing Ratio	0.00%	42.58%	110.72%	100.04%	72.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.21	3.57	3.08	3.51	2.71	1.83	1.04	1.06	0.98	3.60	4.66
Quick Ratio	3.51	2.95	2.50	3.01	2.22	1.51	0.63	0.60	0.50	3.18	4.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	45	27	-13	-15	-44	-41	39	58	39	-9.95	-1.24
Operating Cash Flow to CapEx	3,933.33%	1,347.51%	-1,181.84%	-61.59%	-715.78%	-2,249.54%	381.25%	1,227.84%	384.35%	322.76%	656.84%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-3.06	-2.73	-8.76	0.00	671.20	0.00	-115.75	-25.93
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-0.40	-1.87	-8.37	0.00	723.44	0.00	218.69	350.04
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-1.04	-2.14	-8.74	0.00	664.52	0.00	150.93	296.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.39	1.57	1.49	1.24	1.34	2.06	2.94	2.69	1.75	1.53	1.22
Accounts Receivable Turnover	6.36	6.63	6.42	6.39	7.33	0.00	0.00	0.00	0.00	4.66	5.53
Inventory Turnover	2.68	3.19	3.93	3.64	4.04	3.43	2.86	2.78	2.65	3.21	2.81
Fixed Asset Turnover	54.01	43.36	31.47	0.00	0.00	20.12	22.79	22.88	18.90	25.10	24.80
Accounts Payable Turnover	7.30	6.24	6.10	4.91	4.50	3.66	3.12	3.38	3.25	3.93	4.12
Days Sales Outstanding (DSO)	57.38	55.04	56.85	57.14	49.81	0.00	0.00	0.00	0.00	78.37	66.02
Days Inventory Outstanding (DIO)	136.19	114.26	92.81	100.17	90.32	106.29	127.66	131.30	137.63	113.76	129.89
Days Payable Outstanding (DPO)	50.00	58.46	59.83	74.38	81.09	99.86	116.96	108.12	112.34	92.99	88.65
Cash Conversion Cycle (CCC)	143.57	110.83	89.84	82.93	59.04	6.42	10.71	23.18	25.29	99.14	107.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	109	111	57	54	43	31	4.54	46	38	77	37
Invested Capital Turnover	3.17	3.83	4.85	4.99	6.68	16.85	14.12	7.58	3.86	3.30	3.56
Increase / (Decrease) in Invested Capital	-2.23	54	3.14	10	12	26	-42	7.96	-38	40	7.51
Enterprise Value (EV)	1,329	988	391	731	1,052	838	222	1,373	940	989	1,181
Market Capitalization	1,414	1,021	316	677	1,008	842	268	1,400	970	1,021	1,233
Book Value per Share	$1.31	$1.23	($0.16)	$0.00	$0.00	$0.31	$0.45	$0.66	$0.44	$0.99	$0.84
Tangible Book Value per Share	$1.10	$1.01	($0.38)	($0.23)	($0.24)	$0.06	$0.18	$0.39	$0.04	$0.86	$0.70
Total Capital	213	192	123	141	139	100	50	74	48	108	89
Total Debt	20	49	49	48	48	66	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	18	48	49	48	48	62	0.00	0.00	0.00	0.00	0.00
Net Debt	-84	-33	-17	-39	-48	-3.41	-45	-27	-30	-31	-52
Capital Expenditures (CapEx)	1.68	1.99	1.51	3.22	4.23	1.75	9.39	5.13	6.21	5.83	2.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	44	37	25	19	5.64	-9.40	-43	-25	-32	38	15
Debt-free Net Working Capital (DFNWC)	149	119	91	106	101	60	2.50	2.94	-1.32	70	67
Net Working Capital (NWC)	146	118	91	106	101	56	2.50	2.94	-1.32	70	67
Net Nonoperating Expense (NNE)	0.73	23	20	5.35	18	11	27	1.63	0.24	0.10	0.04
Net Nonoperating Obligations (NNO)	-84	-32	-18	-39	-48	-3.41	-45	-27	-9.71	-31	-52
Total Depreciation and Amortization (D&A)	6.04	3.43	4.05	6.24	9.13	9.02	6.86	5.93	5.62	2.77	2.13
Debt-free, Cash-free Net Working Capital to Revenue	12.70%	11.59%	9.22%	7.88%	2.27%	-3.14%	-11.87%	-7.64%	-14.27%	20.31%	12.64%
Debt-free Net Working Capital to Revenue	42.63%	37.10%	33.84%	43.87%	40.87%	19.94%	0.70%	0.91%	-0.59%	37.12%	56.90%
Net Working Capital to Revenue	41.93%	36.78%	33.84%	43.87%	40.87%	18.69%	0.70%	0.91%	-0.59%	37.12%	56.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.29	$0.40	($0.33)	($0.15)	($0.77)	($0.24)	($0.28)	$0.61	$0.11	$0.28	$0.06
Adjusted Weighted Average Basic Shares Outstanding	146.98M	116.50M	112.91M	110.35M	108.26M	106.95M	105.60M	106.12M	105.93M	105.93M	105.79M
Adjusted Diluted Earnings per Share	$0.28	$0.37	($0.33)	($0.15)	($0.77)	($0.24)	($0.28)	$0.56	$0.11	$0.26	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	149.05M	145.96M	112.91M	110.35M	108.26M	106.95M	105.60M	116.11M	112.44M	113.63M	113.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.24)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	147.37M	146.96M	114.08M	112.36M	111.26M	106.60M	107.10M	106.10M	108.84M	107.81M	106.59M
Normalized Net Operating Profit after Tax (NOPAT)	43	26	-10	-4.90	-31	-14	-2.75	32	0.63	17	6.26
Normalized NOPAT Margin	12.46%	8.08%	-3.85%	-2.02%	-12.51%	-4.85%	-0.76%	10.08%	0.29%	9.11%	5.30%
Pre Tax Income Margin	16.42%	9.53%	-7.37%	-4.98%	-24.79%	-8.55%	-0.95%	14.04%	0.25%	12.96%	5.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-1.42	-2.81	-4.43	0.00	519.25	0.00	283.30	147.92
NOPAT to Interest Expense	0.00	0.00	0.00	-0.99	-1.97	-3.15	0.00	762.72	0.00	343.61	130.47
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-2.07	-3.07	-4.81	0.00	460.33	0.00	215.55	94.63
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-1.64	-2.23	-3.52	0.00	703.80	0.00	275.85	77.17
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	16.34%	0.00%	0.00%	-15.16%	0.00%	-25.26%	105.46%	2,661.03%	136.79%	90.23%

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.13%	7.00%	2.87%	7.32%	18.18%	16.75%	20.72%	21.49%	21.70%	46.37%	7.32%
EBITDA Growth	-17.76%	-14.56%	1.51%	110.09%	1,925.47%	33.51%	306.21%	236.23%	108.42%	369.26%	-4,059.60%
EBIT Growth	-38.12%	-30.06%	0.25%	114.80%	3,975.44%	37.14%	256.46%	212.15%	96.37%	779.32%	-560.74%
NOPAT Growth	-35.81%	-87.20%	-26.15%	62.90%	4,504.13%	406.29%	309.71%	261.99%	96.34%	305.51%	-560.74%
Net Income Growth	-24.17%	-86.09%	-5.14%	1,368.75%	285.85%	13,017.15%	201.28%	111.04%	52.49%	-118.69%	-260.24%
EPS Growth	-16.67%	-86.11%	-16.67%	1,100.00%	200.00%	1,900.00%	166.67%	109.09%	45.45%	-300.00%	-125.00%
Operating Cash Flow Growth	-11.36%	83.11%	53.42%	180.57%	247.68%	282.38%	1,233.79%	358.74%	60.40%	-74.01%	-84.85%
Free Cash Flow Firm Growth	134.42%	252.72%	-1,408.57%	-857.46%	-1,070.92%	-66.78%	67.43%	142.75%	72.77%	207.98%	-221.17%
Invested Capital Growth	-9.48%	-2.00%	85.12%	101.06%	104.77%	95.85%	27.77%	9.62%	7.67%	5.86%	9.38%
Revenue Q/Q Growth	-5.06%	10.53%	-3.61%	2.95%	-2.45%	6.27%	0.56%	13.37%	-3.63%	9.88%	1.21%
EBITDA Q/Q Growth	-15.96%	8.81%	-48.48%	74.58%	-16.93%	29.27%	6.62%	1,583.12%	-94.46%	299.67%	29.56%
EBIT Q/Q Growth	-25.27%	-2.64%	-52.01%	77.21%	-17.18%	39.55%	2.83%	3,297.34%	-102.99%	259.20%	26.29%
NOPAT Q/Q Growth	-7.94%	-5.09%	-56.73%	69.80%	-81.71%	447.69%	-4.57%	4,690.93%	-102.11%	326.86%	26.29%
Net Income Q/Q Growth	-5.58%	-8.12%	-54.07%	90.31%	-82.68%	526.63%	611.17%	124.08%	-1,103.62%	95.09%	22.47%
EPS Q/Q Growth	0.00%	0.00%	-58.33%	100.00%	-83.33%	500.00%	500.00%	116.67%	-200.00%	77.78%	18.18%
Operating Cash Flow Q/Q Growth	-71.79%	-4.29%	-10.04%	264.90%	-41.72%	-19.81%	64.51%	292.07%	28.02%	-686.44%	131.91%
Free Cash Flow Firm Q/Q Growth	96.82%	121.30%	-4.45%	21.40%	-1,967.41%	191.11%	-152.44%	221.51%	-157.22%	189.32%	31.17%
Invested Capital Q/Q Growth	5.56%	-4.51%	-5.45%	-5.02%	14.28%	80.39%	2.69%	-3.27%	9.30%	17.69%	-11.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.23%	81.80%	81.77%	82.97%	84.67%	84.06%	81.90%	83.28%	82.67%	80.68%	81.99%
EBITDA Margin	12.97%	14.66%	14.89%	27.86%	16.43%	18.36%	15.09%	14.23%	0.96%	16.05%	-8.83%
Operating Margin	9.35%	11.90%	13.28%	26.89%	15.58%	17.84%	13.61%	13.34%	-0.47%	15.21%	-10.49%
EBIT Margin	9.19%	11.68%	13.25%	26.62%	15.46%	17.86%	13.60%	13.30%	-0.47%	15.20%	-10.49%
Profit (Net Income) Margin	7.96%	8.01%	9.63%	20.21%	10.93%	61.59%	10.44%	1.48%	-6.95%	-0.56%	-12.45%
Tax Burden Percent	81.55%	66.12%	70.89%	75.92%	81.17%	384.34%	90.47%	13.08%	263.51%	-4.20%	100.63%
Interest Burden Percent	106.24%	103.72%	102.50%	100.01%	87.10%	89.72%	84.88%	84.92%	559.47%	87.18%	117.88%
Effective Tax Rate	18.45%	33.88%	31.01%	24.10%	20.58%	-268.61%	6.27%	-0.81%	0.00%	0.28%	0.00%
Return on Invested Capital (ROIC)	22.21%	24.94%	35.75%	76.92%	43.78%	251.81%	71.79%	69.13%	-1.56%	73.60%	-38.87%
ROIC Less NNEP Spread (ROIC-NNEP)	21.71%	24.72%	34.95%	77.43%	49.71%	266.54%	78.44%	113.38%	22.20%	114.85%	-28.61%
Return on Net Nonoperating Assets (RNNOA)	-7.05%	-8.52%	-12.61%	-20.99%	-8.89%	-60.48%	-26.78%	-31.40%	-5.56%	-38.97%	12.07%
Return on Equity (ROE)	15.16%	16.42%	23.14%	55.93%	34.89%	191.32%	45.01%	37.73%	-7.11%	34.63%	-26.80%
Cash Return on Invested Capital (CROIC)	42.61%	41.23%	43.46%	37.73%	26.91%	32.52%	34.23%	16.28%	-14.13%	-24.37%	-46.50%
Operating Return on Assets (OROA)	13.16%	16.20%	20.99%	44.58%	26.54%	27.97%	23.23%	22.74%	-0.77%	22.66%	-14.51%
Return on Assets (ROA)	11.40%	11.11%	15.25%	33.85%	18.76%	96.47%	17.84%	2.53%	-11.39%	-0.83%	-17.21%
Return on Common Equity (ROCE)	15.16%	16.42%	15.35%	35.06%	20.88%	109.86%	-4.91%	-6.24%	1.13%	-3.71%	4.25%
Return on Equity Simple (ROE_SIMPLE)	19.82%	0.00%	48.87%	52.90%	46.54%	0.00%	326.09%	99.66%	137.59%	0.00%	141.23%
Net Operating Profit after Tax (NOPAT)	6.73	7.31	7.70	18	10	57	10	11	-0.24	11	-4.97
NOPAT Margin	7.63%	7.87%	9.16%	20.41%	12.37%	65.77%	12.76%	13.45%	-0.33%	15.17%	-7.35%
Net Nonoperating Expense Percent (NNEP)	0.51%	0.22%	0.80%	-0.52%	-5.93%	-14.73%	-6.65%	-44.25%	-23.76%	-41.25%	-10.26%
Return On Investment Capital (ROIC_SIMPLE)	3.04%	3.43%	-	-	-	29.77%	-	-	-	36.86%	-
Cost of Revenue to Revenue	18.77%	18.20%	18.23%	17.03%	15.33%	15.94%	18.10%	16.72%	17.33%	19.32%	18.01%
SG&A Expenses to Revenue	67.99%	65.70%	63.67%	63.53%	65.08%	62.59%	64.34%	63.94%	72.90%	67.01%	79.00%
R&D to Revenue	3.77%	3.84%	3.47%	3.45%	3.35%	2.80%	3.76%	4.52%	4.86%	-6.36%	8.79%
Operating Expenses to Revenue	71.87%	69.90%	68.49%	56.08%	69.09%	66.22%	68.29%	69.94%	83.15%	65.47%	92.49%
Earnings before Interest and Taxes (EBIT)	8.11	11	11	23	13	16	11	11	-0.34	11	-7.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	11	14	13	24	14	16	12	12	0.69	12	-5.98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.52	7.32	4.79	6.09	5.75	7.15	636.42	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	6.50	8.72	5.77	7.49	7.24	8.65	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.18	4.05	2.53	3.00	2.68	3.17	2.74	2.59	1.39	1.18	1.33
Price to Earnings (P/E)	27.87	33.33	5.78	6.83	6.36	17.53	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.59%	3.00%	17.31%	14.65%	15.73%	5.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.98	12.20	7.02	8.08	6.83	8.88	14.71	13.94	7.56	6.89	8.16
Enterprise Value to Revenue (EV/Rev)	2.93	3.81	2.34	2.86	2.59	3.07	2.93	2.84	1.67	1.46	1.61
Enterprise Value to EBITDA (EV/EBITDA)	16.68	20.66	11.92	14.56	15.98	24.38	24.52	44.81	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	19.36	22.80	12.72	15.50	17.16	26.63	27.57	57.03	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	26.11	30.81	8.83	10.29	9.59	12.09	28.16	57.27	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	15.75	20.08	13.88	19.18	23.56	36.89	83.23	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	20.01	29.30	20.97	28.61	34.08	36.17	48.22	89.58	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.10	0.12	0.13	0.12	0.34	0.52	0.61	0.65	0.65	0.66
Long-Term Debt to Equity	0.09	0.09	0.10	0.11	0.12	0.34	0.52	0.61	0.65	0.65	0.66
Financial Leverage	-0.32	-0.34	-0.36	-0.27	-0.18	-0.23	-0.34	-0.28	-0.25	-0.34	-0.42
Leverage Ratio	1.37	1.50	1.58	1.64	1.69	1.89	2.17	2.17	2.15	2.15	2.21
Compound Leverage Factor	1.46	1.55	1.61	1.64	1.47	1.70	1.84	1.85	12.01	1.88	2.61
Debt to Total Capital	8.43%	9.49%	10.78%	11.32%	11.10%	25.60%	34.29%	37.96%	39.52%	39.48%	39.91%
Short-Term Debt to Total Capital	0.51%	1.13%	1.90%	1.69%	0.57%	0.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	7.92%	8.36%	8.88%	9.63%	10.53%	25.08%	34.29%	37.96%	39.52%	39.48%	39.91%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	64.78%	71.89%	75.04%	75.14%	76.16%
Common Equity to Total Capital	91.57%	90.51%	89.22%	88.68%	88.90%	74.40%	0.93%	-9.84%	-14.56%	-14.61%	-16.07%
Debt to EBITDA	0.30	0.31	0.33	0.32	0.36	1.21	1.32	2.62	-35.43	-4.55	-2.41
Net Debt to EBITDA	-1.42	-1.31	-1.00	-0.71	-0.54	-0.81	-0.87	-1.06	9.10	1.62	1.23
Long-Term Debt to EBITDA	0.28	0.28	0.27	0.27	0.34	1.19	1.32	2.62	-35.43	-4.55	-2.41
Debt to NOPAT	0.47	0.47	0.24	0.23	0.22	0.60	1.52	3.34	-12.07	-4.71	-2.80
Net Debt to NOPAT	-2.22	-1.95	-0.74	-0.50	-0.32	-0.40	-1.00	-1.36	3.10	1.68	1.43
Long-Term Debt to NOPAT	0.44	0.41	0.20	0.19	0.20	0.59	1.52	3.34	-12.07	-4.71	-2.80
Altman Z-Score	11.60	13.62	9.91	11.63	9.59	7.73	6.48	5.73	3.16	2.80	2.31
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	33.65%	37.32%	40.17%	42.58%	110.91%	116.55%	115.90%	110.72%	115.86%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.70	4.21	4.10	3.85	3.29	3.57	3.54	3.18	3.22	3.08	2.97
Quick Ratio	3.96	3.51	3.41	3.05	2.50	2.95	2.98	2.65	2.59	2.50	2.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	19	9.54	-45	-43	-55	2.70	-2.97	5.66	-4.66	8.14	-9.11
Operating Cash Flow to CapEx	1,405.57%	0.00%	11,476.02%	4,631.42%	97.30%	2,402.11%	2,036.78%	2,600.33%	-639.49%	-843.18%	274.79%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-32.26	0.00	0.00	0.00	-3.00	0.00	-7.17
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	3.54	0.00	0.00	0.00	-2.61	0.00	0.76
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-0.10	0.00	0.00	0.00	-3.01	0.00	0.48
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.43	1.39	1.58	1.67	1.72	1.57	1.71	1.71	1.64	1.49	1.38
Accounts Receivable Turnover	5.91	6.36	6.65	6.69	6.58	6.63	6.88	6.81	6.81	6.42	6.31
Inventory Turnover	2.62	2.68	2.63	2.70	2.82	3.19	3.34	3.48	3.65	3.93	3.26
Fixed Asset Turnover	53.74	54.01	50.62	48.35	44.89	43.36	41.19	0.00	0.00	31.47	0.00
Accounts Payable Turnover	6.86	7.30	7.08	7.17	6.30	6.24	6.13	6.48	6.37	6.10	5.23
Days Sales Outstanding (DSO)	61.79	57.38	54.85	54.55	55.49	55.04	53.05	53.59	53.57	56.85	57.80
Days Inventory Outstanding (DIO)	139.14	136.19	138.68	135.31	129.30	114.26	109.33	104.85	99.97	92.81	111.92
Days Payable Outstanding (DPO)	53.24	50.00	51.52	50.91	57.92	58.46	59.52	56.34	57.28	59.83	69.81
Cash Conversion Cycle (CCC)	147.70	143.57	142.01	138.95	126.87	110.83	102.86	102.10	96.26	89.84	99.91
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	115	109	114	121	127	111	62	60	62	57	48
Invested Capital Turnover	2.91	3.17	3.90	3.77	3.54	3.83	5.63	5.14	4.69	4.85	5.29
Increase / (Decrease) in Invested Capital	-12	-2.23	52	61	65	54	13	5.27	4.42	3.14	4.14
Enterprise Value (EV)	1,032	1,329	801	975	867	988	907	837	469	391	394
Market Capitalization	1,120	1,414	868	1,023	896	1,021	846	764	389	316	326
Book Value per Share	$1.38	$1.31	$1.23	$1.14	$1.06	$1.23	$0.01	($0.11)	($0.16)	($0.16)	($0.17)
Tangible Book Value per Share	$1.17	$1.10	$1.02	$0.93	$0.85	$1.01	($0.20)	($0.33)	($0.38)	($0.38)	($0.39)
Total Capital	221	213	203	189	175	192	143	129	123	123	121
Total Debt	19	20	22	21	19	49	49	49	49	49	48
Total Long-Term Debt	18	18	18	18	18	48	49	49	49	49	48
Net Debt	-88	-84	-67	-48	-29	-33	-32	-20	-13	-17	-25
Capital Expenditures (CapEx)	0.38	-5.10	0.17	0.47	6.14	0.43	0.63	0.30	0.63	0.67	0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	52	44	45	48	49	37	30	28	30	25	17
Debt-free Net Working Capital (DFNWC)	159	149	134	117	98	119	111	97	91	91	90
Net Working Capital (NWC)	157	146	130	114	97	118	111	97	91	91	90
Net Nonoperating Expense (NNE)	-0.29	-0.13	-0.39	0.17	1.22	3.63	1.89	9.73	4.75	12	3.45
Net Nonoperating Obligations (NNO)	-88	-84	-67	-47	-29	-32	-32	-20	-13	-18	-25
Total Depreciation and Amortization (D&A)	3.34	2.77	1.37	1.08	0.82	0.43	1.22	0.76	1.03	0.63	1.12
Debt-free, Cash-free Net Working Capital to Revenue	14.81%	12.70%	13.20%	14.15%	14.69%	11.59%	9.61%	9.53%	10.55%	9.22%	6.94%
Debt-free Net Working Capital to Revenue	45.01%	42.63%	39.11%	34.42%	29.19%	37.10%	35.88%	32.80%	32.37%	33.84%	36.92%
Net Working Capital to Revenue	44.69%	41.93%	37.98%	33.49%	28.89%	36.78%	35.88%	32.80%	32.37%	33.84%	36.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.05	$0.06	$0.05	$0.12	$0.06	$0.40	$0.06	$0.00	($0.06)	($0.02)	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	147.27M	146.98M	146.96M	147.33M	146.40M	116.50M	116.30M	115.87M	114.40M	112.91M	113.45M
Adjusted Diluted Earnings per Share	$0.05	$0.05	$0.05	$0.12	$0.06	$0.36	$0.06	$0.00	($0.06)	($0.02)	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	149.68M	149.05M	148.37M	148.90M	150.03M	145.96M	119.33M	115.87M	114.40M	112.91M	113.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	147.70M	147.37M	146.95M	146.81M	147.60M	146.96M	116.38M	116.11M	115.60M	114.08M	113.67M
Normalized Net Operating Profit after Tax (NOPAT)	6.73	7.37	7.91	18	11	11	10	7.59	-0.24	11	-4.97
Normalized NOPAT Margin	7.63%	7.93%	9.41%	20.41%	12.42%	12.49%	12.76%	9.34%	-0.33%	15.17%	-7.35%
Pre Tax Income Margin	9.76%	12.11%	13.58%	26.62%	13.47%	16.02%	11.54%	11.29%	-2.64%	13.25%	-12.37%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	7.75	0.00	0.00	0.00	-0.22	0.00	-5.59
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	6.20	0.00	0.00	0.00	-0.15	0.00	-3.92
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	4.12	0.00	0.00	0.00	-0.63	0.00	-5.87
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	2.57	0.00	0.00	0.00	-0.56	0.00	-4.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	16.34%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About MiMedx Group's Financials

When does MiMedx Group's fiscal year end?

According to the most recent income statement we have on file, MiMedx Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has MiMedx Group's net income changed over the last 10 years?

MiMedx Group's net income appears to be on an upward trend, with a most recent value of $42.42 million in 2024, rising from $6.22 million in 2014. The previous period was $58.23 million in 2023. View MiMedx Group's forecast to see where analysts expect MiMedx Group to go next.

What is MiMedx Group's operating income?

MiMedx Group's total operating income in 2024 was $58.87 million, based on the following breakdown:

Total Gross Profit: $288.81 million
Total Operating Expenses: $229.94 million

How has MiMedx Group revenue changed over the last 10 years?

Over the last 10 years, MiMedx Group's total revenue changed from $118.22 million in 2014 to $348.88 million in 2024, a change of 195.1%.

How much debt does MiMedx Group have?

MiMedx Group's total liabilities were at $70.81 million at the end of 2024, a 26.5% decrease from 2023, and a 255.3% increase since 2014.

How much cash does MiMedx Group have?

In the past 10 years, MiMedx Group's cash and equivalents has ranged from $27.48 million in 2017 to $104.42 million in 2024, and is currently $104.42 million as of their latest financial filing in 2024.

How has MiMedx Group's book value per share changed over the last 10 years?

Over the last 10 years, MiMedx Group's book value per share changed from 0.84 in 2014 to 1.31 in 2024, a change of 57.3%.

Related Companies

This page (NASDAQ:MDXG) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Financials

Frequently Asked Questions About MiMedx Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Financials

Annual Income Statements for MiMedx Group

Quarterly Income Statements for MiMedx Group

Annual Cash Flow Statements for MiMedx Group

Quarterly Cash Flow Statements for MiMedx Group

Annual Balance Sheets for MiMedx Group

Quarterly Balance Sheets for MiMedx Group

Annual Metrics And Ratios for MiMedx Group

Quarterly Metrics And Ratios for MiMedx Group

Frequently Asked Questions About MiMedx Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools